Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 244 of 6351
-
Boosting CAR t: early second dose may keep childhood leukemia at bay
Disease control OngoingThe researchers are doing this study to see if early reinfusion of tisagenlecleucel can keep participants in B-CEll ApLasia at 6 months after their first infusion. The researchers will also look at the safety of early reinfusion and how effective it is at treating B-ALL.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can a new drug shrink Hard-to-Treat eye cancer?
Disease control OngoingThis is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas h…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a Diamond-Coated rotating crown unclog calcified heart arteries?
Disease control CompletedThis is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary atherectomy system for the treatment of patients with coronary calcification.
Sponsor: Shanghai MicroPort Rhythm MedTech Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a pill tame thyroid eye disease?
Disease control CompletedThe overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twice daily (BID) vs. placebo, at 24 weeks in the treatment of subjects with active, moderate to severe thyroid eye disease (TED).
Phase 2/3 • Sponsor: Sling Therapeutics, Inc. • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a higher dose of heart radiation stop dangerous rhythms?
Disease control Recruiting nowThe objective of this study is to demonstrate that higher radiation doses are necessary to induce transmural scar formation which is currently assumed to be the underlying mechanism of successful long-term efficacy of VT treatment and therefore dose-escalation will lead to a sign…
Phase 1 • Sponsor: University of Zurich • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.
Phase 2 • Sponsor: Juntendo University • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Hope for rare brain disease: new drug trial targets movement and daily life
Disease control Recruiting nowA pivotal, randomized, double-blind, placebo controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Niemann Pick disease type C (NPC). The objective of this study is to evaluate the safety, tolerability and efficacy of N-acetyl-L-leu…
Phase 3 • Sponsor: IntraBio Inc • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Bladder cancer cocktail aims to wipe out tumors before surgery
Disease control OngoingCurrent treatment of localized muscle-invasive bladder cancer is still associated with high relapse and death rate as well as the need for complete bladder resection or irradiation. The primary objective of this trial is to increase the rate of pathologic complete remission (pCR…
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Blood thinner may stop autoimmune disease before it starts
Prevention Recruiting nowSystemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific anti-nuc…
Phase 2/3 • Sponsor: University Hospital, Bordeaux • Aim: Prevention
Last updated Jul 09, 2026 00:00 UTC
-
Two-Drug combo aims to outsmart resistant hodgkin lymphoma
Disease control Stopped earlyThe purpose of this study is to test the safety and efficacy of magrolimab in combination with pembrolizumab in patients with Hodgkin lymphoma.
Phase 2 • Sponsor: Ranjana Advani • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New pill takes on tough lung cancer in Late-Stage trial
Disease control OngoingThis is a phase III randomized open label study designed to compare JDQ443 as monotherapy to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previously treated with a platinum-based chemotherapy and immune ch…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New antibody combo aims to treat brain lymphoma
Disease control Recruiting nowThis is a single arm open-label multicenter phase I/II investigation of combination lenalidomide/Tafasitamab in patients with relapsed central nervous system (CNS) lymphoma. This is the first study to examine a naked anti-CD19 monoclonal antibody in relapsed CNS lymphoma patients…
Phase 1/2 • Sponsor: James Rubenstein • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Could a pill replace blood transfusions for kids with rare anemia?
Disease control OngoingACTIVATE-KidsT (AG348-C-022) is a multicenter study designed to evaluate the efficacy and safety of treatment with mitapivat compared with placebo in pediatric participants with pyruvate kinase deficiency (PK deficiency) who are regularly receiving blood transfusions. Participant…
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a diabetes drug shield heart transplant patients from kidney failure?
Disease control OngoingKidney failure is common in heart transplant recipients and is a major cause of morbidity and mortality. Sodium-glucose transporter 2 (SGLT2) inhibitors were developed as antidiabetics but were subsequently shown to reduce the incidence of adverse cardiovascular outcomes and prot…
Phase 3 • Sponsor: Oslo University Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Can a vaccine boost immunotherapy against a stubborn cancer?
Disease control CompletedThis is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimen…
Phase 2 • Sponsor: Treos Bio Limited • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Shielding the ovaries: a drug may help young breast cancer patients preserve fertility during chemo
Disease control CompletedThe purpose of this study is to investigate the benefits of gonadotropin-releasing hormone agonist administration during chemotherapy on preserving ovarian function and Fertility in Premenopausal breast cancer patients, as assessed by anti-mullerian hormone levels, luteinizing ho…
Sponsor: Helwan University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a targeted pill combo tame acute myeloid leukemia without harsh chemo?
Disease control CompletedThis single-arm interventional study evaluated the short-term outcome of one 28-day cycle of venetoclax combined with a hypomethylating agent (azacitidine or decitabine) in adults with newly diagnosed acute myeloid leukemia who could not receive intensive induction chemotherapy. …
Phase 4 • Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New eczema drug shows promise in large trial
Disease control CompletedThe purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a pill tame the relentless hunger of Prader-Willi syndrome?
Disease control CompletedA Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Phase 2 • Sponsor: Aardvark Therapeutics, Inc. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Peer navigators and mobile clinics aim to slash HIV rates in rural south african youth
Disease control CompletedStudy Hypothesis: Social mobilisation will attract and engage young people into decentralised sexual reproductive health (SRH) services where HIV prevention is tailored to need. Decentralised risk informed (differentiated) biosocial HIV prevention will reduce the overall prevalen…
Sponsor: Africa Health Research Institute • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC